Search

Huw R Tanner

from San Francisco, CA
Age ~45
Get Report
Also known as:
Huw R Tannet
Related to:
Jared A Rasmussen, 35Travis R Rasmussen, 42
Connected to:
Aj Tanner, 40Andy W Tanner, 38Ann Tanner, 67Annamarie G Tanner, 57Annmarie M Tanner, 67Ashton D Tanner, 36Becca A Tanner, 30Bo N Tanner, 32Bradley W Tanner, 37Carlis A Tanner, 77

Huw Tanner Phones & Addresses

  • San Francisco, CA
  • Alameda, CA
  • Newport Beach, CA
  • Corona del Mar, CA

Work

Company: Unity biotechnology 2017 Position: Head of portfolio planning, program and alliance management, vice president

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Cambridge 2002 to 2006 Specialities: Philosophy, Organic Chemistry

Skills

Drug Discovery • Pharmaceutical Industry • Medicinal Chemistry • Organic Synthesis • Drug Development • Biotechnology • Drug Design • Synthetic Organic Chemistry • Oncology • Clinical Development • Organic Chemistry • Cross Functional Team Leadership • Project Management • Strategy • Team Leadership • Chemistry • Life Sciences • Adme • Team Management • Strategic Planning • Risk Assessment • Risk Management • Management • Mentoring • Coaching • Strategic Partnerships • Team Building • Infectious Diseases • Clinical Trials • Lead Change • Ind • Pharmaceutics • Lifesciences • Inflammation • Drug Safety • Pharmacokinetics • Pharmacodynamics • In Vitro • Program Management • Project Planning • Cardiovascular Disease • Gastrointestinal Disorders • Microsoft Project • Regulatory Submissions

Languages

English • French • Welsh

Industries

Biotechnology

Resumes

Resumes

Huw Tanner Photo 1

Head Of Portfolio Planning, Program And Alliance

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Unity Biotechnology
Head of Portfolio Planning, Program and Alliance Management, Vice President
California Life Sciences Association (Clsa)
Advisory Fellow and Mentor - Fast Advisory Program
Denali Therapeutics Oct 2015 - 2017
Program, Portfolio and Alliance Management, Director
Theravance Biopharma Us, Inc. May 2014 - Oct 2015
Associate Director, Research and Early Development Program Management
Novartis May 2013 - May 2014
Research Project Manager
Education:
University of Cambridge 2002 - 2006
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry Dyson School of Design Engineering 1997 - 2002
Imperial College London
Skills:
Drug Discovery
Pharmaceutical Industry
Medicinal Chemistry
Organic Synthesis
Drug Development
Biotechnology
Drug Design
Synthetic Organic Chemistry
Oncology
Clinical Development
Organic Chemistry
Cross Functional Team Leadership
Project Management
Strategy
Team Leadership
Chemistry
Life Sciences
Adme
Team Management
Strategic Planning
Risk Assessment
Risk Management
Management
Mentoring
Coaching
Strategic Partnerships
Team Building
Infectious Diseases
Clinical Trials
Lead Change
Ind
Pharmaceutics
Lifesciences
Inflammation
Drug Safety
Pharmacokinetics
Pharmacodynamics
In Vitro
Program Management
Project Planning
Cardiovascular Disease
Gastrointestinal Disorders
Microsoft Project
Regulatory Submissions
Languages:
English
French
Welsh

Publications

Us Patents

Cyclic Ether Compounds Useful As Kinase Inhibitors

View page
US Patent:
20130109682, May 2, 2013
Filed:
Jul 4, 2011
Appl. No.:
13/807993
Inventors:
Matthew Burger - Albany CA, US
Yu Ding - Union City CA, US
Wooseok Han - San Ramon CA, US
Mika Lindvall - Oakland CA, US
Gisele A. Nishiguchi - Albany CA, US
Alice Rico - Castro Valley CA, US
Aaron Smith - Fremont CA, US
Huw Tanner - Alameda CA, US
Lifeng Wan - Union City CA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
C07D 417/14
A61K 31/444
A61K 45/06
A61K 31/506
A61K 31/501
A61K 31/541
C07D 405/14
A61K 31/497
US Classification:
5142278, 546256, 514333, 544405, 51425505, 544322, 514256, 544238, 51425203, 544 582
Abstract:
The present invention provides certain compounds of Formula (I):and pharmaceutically acceptable salts thereof, as further described herein. Also provided are formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.

Novel Ring-Substituted N-Pyridinyl Amides As Kinase Inhibitors

View page
US Patent:
20130336965, Dec 19, 2013
Filed:
May 20, 2013
Appl. No.:
13/897927
Inventors:
- Basel, CH
Gisele Nishiguchi - Albany CA, US
Alice Rico - Castro Valley CA, US
Robert Lowell Simmons - San Francisco CA, US
Benjamin Taft - Oakland CA, US
Huw Tanner - Alameda CA, US
Assignee:
Novartis AG - Basel
International Classification:
C07D 213/81
A61K 31/506
A61K 31/4545
A61K 31/444
A61K 31/4439
A61K 45/06
C07D 405/14
C07F 9/6558
C07D 401/14
C07D 417/12
C07D 409/14
C07D 417/14
A61K 31/675
C07D 401/12
US Classification:
4241331, 424649, 514 34, 514 49, 514 64, 514 89, 514110, 514249, 51425218, 514256, 514274, 514278, 514283, 514318, 514332, 514333, 514342, 544322, 544333, 546 15, 546 22, 546194, 546256, 546262, 5462707
Abstract:
The present invention provides a compound of formula (A):as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

Tetrasubstituted Cyclohexyl Compounds As Kinase Inhibitors

View page
US Patent:
20120225061, Sep 6, 2012
Filed:
Mar 1, 2012
Appl. No.:
13/410203
Inventors:
Matthew Burger - Albany CA, US
Yu Ding - Union City CA, US
Wooseok Han - San Ramon CA, US
Gisele Nishiguchi - Albany CA, US
Alice Rico - Castro Valley CA, US
Robert Lowell Simmons - San Francisco CA, US
Aaron R. Smith - Fremont CA, US
Victoriano Tamez, JR. - Emeryville CA, US
Huw Tanner - Alameda CA, US
Lifeng Wan - Union City CA, US
International Classification:
A61K 31/444
A61K 31/506
A61K 31/497
C07D 413/14
A61K 31/5377
A61K 31/4745
A61K 31/7068
A61K 31/513
A61K 31/704
A61K 31/519
A61K 33/24
A61K 31/664
A61K 39/395
A61P 35/00
A61P 35/02
A61P 37/00
A61P 1/00
C07D 401/12
US Classification:
4241331, 546262, 514332, 544322, 514256, 544405, 51425505, 544131, 5142355, 514283, 514 49, 514274, 514 34, 514249, 424649, 514110, 51425218
Abstract:
The present invention provides a compound of formula (I):as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

Novel Kinase Inhibitors

View page
US Patent:
20120225062, Sep 6, 2012
Filed:
Mar 2, 2012
Appl. No.:
13/410845
Inventors:
Matthew Burger - Albany CA, US
Gisele Nishiguchi - Albany CA, US
Timothy D. Machajewski - Martinez CA, US
Alice Rico - Castro Valley CA, US
Robert Lowell Simmons - San Francisco CA, US
Aaron R. Smith - Fremont CA, US
Victoriano Tamez, JR. - Emeryville CA, US
Huw Tanner - Alameda CA, US
Lifeng Wan - Union City CA, US
International Classification:
C07D 401/12
A61K 31/444
A61K 31/4545
C07D 413/14
A61K 31/4375
A61K 31/7068
A61K 31/513
A61K 31/351
A61K 31/519
A61K 31/282
A61K 33/24
A61K 31/675
A61K 31/506
A61K 31/165
A61P 35/04
A61K 35/02
A61P 37/00
A61P 1/04
A61P 19/02
C07D 401/14
US Classification:
4241331, 546262, 546194, 514332, 514318, 546256, 544131, 5142355, 514283, 514 49, 514274, 514459, 51425505, 514492, 424649, 514 90, 51425218, 514154
Abstract:
The present invention provides compounds of Formula I:and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.

Biaryl Amide Compounds As Kinase Inhibitors

View page
US Patent:
20190175606, Jun 13, 2019
Filed:
Feb 12, 2019
Appl. No.:
16/274165
Inventors:
- Basel, CH
Paul Andrew BARSANTI - Pleasant Hill CA, US
Matthew T. BURGER - Cambridge MA, US
Michael Patrick DILLON - Castro Valley CA, US
Alan DIPESA - Boston MA, US
Cheng HU - San Mateo CA, US
Yan LOU - Pleasanton CA, US
Gisele A. NISHIGUCHI - Arlington MA, US
Yue PAN - Lexington MA, US
Valery Rostislavovich POLYAKOV - Moraga CA, US
Savithri RAMURTHY - Walnut Creek CA, US
Alice C. RICO - Castro Valley CA, US
Lina Quattrocchio SETTI - Fremont CA, US
Aaron SMITH - Fremont CA, US
Sharadha SUBRAMANIAN - San Ramon CA, US
Benjamin R. TAFT - Emeryville CA, US
Huw Roland TANNER - San Francisco CA, US
Lifeng WAN - Emeryville CA, US
Naeem YUSUFF - Cambridge MA, US
International Classification:
A61K 31/5377
C07D 493/10
C07D 403/12
C07D 413/14
C07D 413/12
C07D 403/04
C07D 401/12
C07D 277/42
C07D 239/48
C07D 239/47
C07D 239/42
C07D 237/20
C07D 213/74
A61K 45/06
A61K 31/541
C07D 413/04
C07D 491/08
C07B 59/00
C07D 417/12
C07D 237/24
C07D 491/04
A61K 31/444
A61K 31/501
C07D 513/04
C07D 491/048
A61K 31/5375
C07D 213/81
C07D 213/82
C07D 213/84
C07D 237/22
C07D 409/14
C07D 498/08
C07D 495/04
C07D 493/04
C07D 491/107
C07D 263/58
C07D 487/04
C07D 471/04
C07D 241/20
C07D 405/12
C07D 405/04
C07D 401/04
C07D 233/88
C07D 213/75
C07D 405/14
C07D 401/14
Abstract:
The present invention provides compounds of Formula (I)as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Compounds And Compositions As Raf Kinase Inhibitors

View page
US Patent:
20180170917, Jun 21, 2018
Filed:
Sep 11, 2015
Appl. No.:
15/510609
Inventors:
- Basel, CH
Matthew T. BURGER - Belmont MA, US
Michael Patrick DILLON - Castro Valley CA, US
Yan LOU - Pleasanton CA, US
Gisele A. NISHIGUCHI - Arlington MA, US
Savithri RAMURTHY - Emeryville CA, US
Alice C. RICO - Castro Valley CA, US
Vivek RAUNIYAR - Cambridge MA, US
Martin SENDZIK - Belmont MA, US
Sharadha SUBRAMANIAN - San Ramon CA, US
Lina Quattrocchio SETTI - Fremont CA, US
Benjamin R. TAFT - Oakland CA, US
Huw Rowland TANNER - San Francisco CA, US
Lifeng WAN - Union City CA, US
International Classification:
C07D 405/14
C07D 405/12
C07D 305/06
C07D 413/14
A61P 35/00
Abstract:
The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Compounds And Compositions As Kinase Inhibitors

View page
US Patent:
20170260200, Sep 14, 2017
Filed:
Sep 11, 2015
Appl. No.:
15/510613
Inventors:
- Basel, CH
Matthew T. BURGER - Belmont MA, US
Yan LOU - Pleasanton CA, US
Gisele A. NISHIGUCHI - Arlington MA, US
Valery Rostislavovich POLYAKOV - Morage CA, US
Savithri RAMURTHY - Emeryville CA, US
Sharadha SUBRAMANIAN - San Ramon CA, US
Benjamin R. TAFT - Oakland CA, US
Huw Rowland TANNER - San Francisco CA, US
Lifeng WAN - Union City CA, US
International Classification:
C07D 498/08
A61K 31/4418
A61K 31/444
C07D 401/14
C07D 213/74
C07D 405/12
A61K 31/541
A61K 31/5377
C07D 401/04
C07D 405/14
A61K 31/496
C07D 413/14
C07D 451/02
A61K 31/501
C07D 213/85
Abstract:
The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Biaryl Amide Compounds As Kinase Inhibitors

View page
US Patent:
20170260207, Sep 14, 2017
Filed:
May 22, 2017
Appl. No.:
15/601423
Inventors:
- Basel, CH
Paul Andrew BARSANTI - Pleasant Hill CA, US
Matthew T. BURGER - Cambridge MA, US
Michael Patrick DILLON - Cambridge MA, US
Alan DIPESA - Bronx NY, US
Cheng HU - San Mateo CA, US
Yan LOU - Pleasanton CA, US
Gisele A. NISHIGUCHI - Cambridge MA, US
Yue PAN - Cambridge MA, US
Valery Rostislavovich POLYAKOV - Emeryville CA, US
Savithri RAMURTHY - Cambridge MA, US
Alice C. RICO - Emeryville CA, US
Lina Quattrocchio SETTI - Fremont CA, US
Aaron SMITH - Emeryville CA, US
Sharadha SUBRAMANIAN - Emeryville CA, US
Benjamin R. TAFT - Emeryville CA, US
Huw Roland TANNER - San Francisco CA, US
Lifeng WAN - Emeryville CA, US
Naeem YUSUFF - Cambridge MA, US
International Classification:
C07D 513/04
A61K 31/5377
C07D 213/74
C07D 237/22
C07D 213/84
C07D 213/81
C07D 213/75
C07D 401/14
C07D 405/14
C07D 413/12
C07D 413/14
C07D 491/08
A61K 31/444
C07D 241/20
C07D 401/04
C07D 237/24
C07D 237/20
A61K 31/501
C07D 239/48
C07D 403/04
C07D 487/04
C07D 471/04
C07D 263/58
C07D 495/04
C07D 491/04
C07D 409/14
C07D 413/04
C07B 59/00
C07D 401/12
Abstract:
The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
Control profile
Huw R Tanner from San Francisco, CA, age ~45 Get Report